A Research Registry on Aggressive PitNETs

Endocrine Tumor Clinical Trial

— RECAPitNETT  

Official title:

A Research Registry on Aggressive PitNETs

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05974696
• Other study ID #: 69HCL23_0026
• Status: Recruiting
• Start date: June 15, 2023
• Est. completion date: June 15, 2029

Study information

• Verified date: July 2023
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours. The multidisciplinary consultation meeting (RCP), organised by the reference centre for rare diseases of the pituitary gland, dedicated to aggressive pituitary tumours and carcinomas (HYPOcare), which is unique in France and brings together national experts, currently makes it possible to orientate the management of patients with an aggressive pituitary tumour. With more than 80 patient files discussed since its inception, the patient cohort via the HYPOcare RCP is one of the largest both nationally and internationally. At present, this data source is only dedicated to the clinical management of the files without the possibility of carrying out research work

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: June 15, 2029
• Est. primary completion date: June 15, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

• Inclusion Criteria :

• Patients with a diagnosis of pituitary tumour

• Patients whose file has been presented to the national HYPOcare RCP

• Exclusion Criteria :

• Patients objecting to participating in this research

Related Conditions & MeSH terms

• Endocrine Gland Neoplasms
• Endocrine Tumor

Locations

Country	Name	City	State
France	Hospices Civils de Lyon - Groupement Hospitalier Est	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterisation of aggressiveness of pituitary tumours by tanscriptome analysis	Molecular and transcriptomic signature of aggressiveness of pituitary tumours predictive of prognosis	3 years